Aptamer Group PLC AGM Statement (9073W)
December 15 2023 - 1:00AM
UK Regulatory
TIDMAPTA
RNS Number : 9073W
Aptamer Group PLC
15 December 2023
15 December 2023
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Annual General Meeting Statement
Aptamer Group plc (AIM: APTA), the developer of novel Optimer
(R) binders to enable innovation in the life sciences industry,
will hold its Annual General Meeting (AGM) at 10:00 am today at the
offices of Aptamer Group plc, Windmill House, Innovation Way, York,
YO10 5BR.
Since the Group was recapitalised in August 2023, it has made
significant technical and commercial progress. This includes a
reduction of the cost base, streamlining of the production
processes for increased production capacity and a reduction of
material requirements from customers. The Group has continued to
build and convert the commercial pipeline, including the recent
announcement of a partnership with a genetic medicines company for
Optimer development to support targeted delivery of new medicines.
No new material information will be provided.
The results of the AGM will be announced to the London Stock
Exchange and placed on the Group's website, in the usual way, as
soon as practicable after the conclusion of the AGM.
- ENDS -
For further information, please contact:
Aptamer Group plc
Steve Hull +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Mark Brady / Adam Dawes +44 (0) 20 3368 3550
-----------------------
T urner Pope I nvestments (TPI) Limited
- B roker
J ames Pope / Andrew Thacker +44 (0) 20 36 57 0 050
-----------------------
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its
proprietary Optimer (R) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers.
Optimer binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global affinity ligand
market is currently worth over $170 billion.
Aptamer has successfully delivered projects for a range of
global pharma companies, diagnostic development companies, and
research institutes, covering multiple application areas with the
objective of establishing royalty-bearing licenses.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMTIBMTMTMBTRJ
(END) Dow Jones Newswires
December 15, 2023 02:00 ET (07:00 GMT)
Aptamer (LSE:APTA)
Historical Stock Chart
From Apr 2024 to May 2024
Aptamer (LSE:APTA)
Historical Stock Chart
From May 2023 to May 2024